{"id":290891,"date":"2026-10-07T09:21:00","date_gmt":"2026-10-07T03:51:00","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=290891"},"modified":"2026-10-07T09:21:00","modified_gmt":"2026-10-07T03:51:00","slug":"pharma-ingredient-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-ingredient-stocks-strong-roadmap\/","title":{"rendered":"3 Pharma Ingredient Stocks With a Strong Future Roadmap: Acutaas Chemicals, Sudeep Pharma and Anthem Biosciences"},"content":{"rendered":"

Acutaas Rs 3,156.70, P\/E 66.70. Sudeep Pharma Rs 1,158.40, P\/E 71.22. Anthem Biosciences Rs 890.35, P\/E 87.04. Closing prices of 6 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Pharma ingredient stocks with the clearest long-term roadmaps today include Acutaas Chemicals in pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives, Sudeep Pharma in pharmaceutical excipients and nutrition ingredients and Anthem Biosciences in contract research, development and manufacturing for pharma and biotech customers. FY26 revenue growth was 34.9% at Acutaas, 31.2% at Sudeep Pharma and 18.1% at Anthem Biosciences. P\/E stands at 66.70 for Acutaas (industry 37.19), 71.22 for Sudeep Pharma (industry 35.84) and 87.04 for Anthem Biosciences (industry 37.19). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Pharma ingredient stocks give investors exposure to makers of intermediates, excipients and contract research services that sit behind finished medicines. Results depend on customer contracts, capacity use and operating margin, which is why margin trends matter as much as headline growth.<\/p>\n

This list covers three contract research and ingredient stocks: Acutaas Chemicals for pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives, Sudeep Pharma for pharmaceutical excipients and nutrition ingredients and Anthem Biosciences for contract research, development and manufacturing for pharma and biotech customers. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n